Jaguar Health, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company achieved total revenue of $20.3 million, a substantial increase from $2.2 million in the same period last year, primarily driven by a $19 million rise in license revenue following a licensing agreement with Woodward Specialty LLC. This agreement, finalized on January 12, 2026, allows Woodward to market Jaguar's Mytesi and Canalevia products, contributing to the overall revenue growth. Despite this increase, product revenue from Mytesi and other offerings saw a decline, totaling $1.2 million compared to $2.2 million in the previous year.
Operating expenses for the quarter decreased to $10.1 million from $11.6 million year-over-year, reflecting a reduction in sales and marketing costs as the company transitioned to a licensing model. The company reported an operating income of $10.2 million, a significant turnaround from an operating loss of $9.4 million in the prior year. Net income for the quarter was $8.7 million, compared to a net loss of $10.6 million in the same period last year. This improvement in profitability was also influenced by a decrease in interest expenses and changes in the fair value of financial instruments.
Jaguar Health's balance sheet as of March 31, 2026, showed total assets of $37.4 million, a slight decrease from $38.3 million at the end of 2025. The company reported a stockholders' deficit of $15.8 million, down from $18.7 million, indicating a gradual improvement in its financial position. The company had cash and restricted cash totaling $10.1 million, which includes $2.8 million in restricted cash related to a secured promissory note. The company continues to face challenges, including an accumulated deficit of $391.1 million, raising concerns about its ability to sustain operations without additional financing.
Strategically, Jaguar Health has made significant moves, including the establishment of JAGX Holdings, a subsidiary formed to manage cash collateral for its obligations under a note purchase agreement. The company is also focused on expanding its product offerings, particularly in the human health sector, with ongoing clinical trials for crofelemer aimed at treating conditions like short bowel syndrome and microvillus inclusion disease. The company plans to submit a clinical study report to the FDA in the second half of 2026, which could further enhance its market position.
Looking ahead, Jaguar Health anticipates continued investment in research and development, particularly for its pipeline of products. The company is actively seeking additional financing to support its operations and product development initiatives. Despite recent improvements in liquidity, management acknowledges the ongoing need for capital to fund its strategic objectives and maintain compliance with Nasdaq listing requirements. The company is committed to exploring various financing options, including equity and debt financing, to ensure its long-term viability.
About Jaguar Health, Inc.
Jaguar Health, Inc. develops plant-derived prescription medicines targeting gastrointestinal disorders in humans and animals. Its core products include crofelemer-based drugs like Mytesi for HIV-related diarrhea and Canalevia for canine diarrhea. The company focuses on unmet medical needs such as cancer therapy-related diarrhea, rare diseases, and supportive care, leveraging sustainable botanical sources and proprietary formulations to provide first-in-class, natural treatment options globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.